NuCana plc ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Free Cash Flow -$10.1MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Gross Margin | 0.0% |
Returns
-120.7%ROE
-98.4%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio5.60x
Net Debt-$23.6Mnet cash position
Cash & Equivalents$24.3M
Quality Metrics
Piotroski F-Score4 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPSFY2025: $0.00
Dividend
No dividend
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| ProTide Oncology Pipeline | $0 | 0.0% | View detailsAdvancing Phase 2 clinical trials for NUC-7738 in combination with pembrolizumab for melanoma, with final data expected in late 2026. |
Financials converted at 0.7425 from GBP.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.